<DOC>
	<DOC>NCT00060476</DOC>
	<brief_summary>To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.</brief_summary>
	<brief_title>Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)</brief_title>
	<detailed_description>The duration of treatment is 6 years.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<criteria>Regular PSA testing and study biopsies required.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>